Skip to main navigation
  • IR Home
  • News
  • Events & Presentations
  • Governance
    • Our Team
    • Board of Directors
    • Committee Composition
    • Documents & Charters
  • Financials
    • SEC Filings
  • Stock Info
    • Stock Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • IR Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR

News Releases

May 10, 2022
Rallybio Reports First Quarter 2022 Financial Results
May 10, 2022
Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi
Apr 04, 2022
Rallybio Appoints Christine A. Nash and Hui Liu, Ph.D., to Its Board of Directors
Mar 15, 2022
Rallybio Reports Fourth Quarter and Full Year 2021 Financial Results
Feb 28, 2022
Rallybio to Present at the Cowen 42nd Annual Health Care Conference
Jan 18, 2022
Ami Bavishi Joins Rallybio to Lead Investor Relations and Corporate Communications
Jan 06, 2022
Rallybio Highlights Portfolio Advances and Outlines Expected Upcoming Milestones for 2022

Investor Tools

Unimagined therapies. Undreamed outcomes.

Rallybio Newsroom
Linkedin

info@rallybio.com

234 Church Street
Suite 1020
New Haven, CT 06510

203-859-3820

© 2022 Rallybio | Terms of Use | Privacy Policy